DVHGF
vs
S&P 500
DVHGF
S&P 500
Over the past 12 months, DVHGF has underperformed S&P 500, delivering a return of +23% compared to the S&P 500's +26% growth.
Stocks Performance
DVHGF vs S&P 500
Performance Gap
DVHGF vs S&P 500
Performance By Year
DVHGF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Devonian Health Group Inc
Glance View
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Pointe-Claire, Quebec. The company went IPO on 2014-09-09. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies, as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a Phase II clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The firm is also involved in the development of cosmeceutical products.
